0
(Adds details and background throughout) Nov 16 (Reuters) – Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)